SC
EUCRU

Sculptor Capital’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Sculptor Capital’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed – – 985
2022
Q3 		$0 Hold
7
– – ﹤0.01% 1234
2022
Q2 		$0 Sell
7
-79,143
-100% -$786K ﹤0.01% 1314
2022
Q1 		$780K Buy
+79,150
New +$785K 0.01% 715

Other funds holding EUCRU

Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Sculptor Capital's EUCRU Position: Q4 2022 in Review

Sculptor Capital sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 7 shares.

Sculptor Capital first reported a position in EUCRU in Q1 2022 and held it in 3 quarters. The position peaked at $780K in Q1 2022. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

  • Sculptor Capital reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
  • Sculptor Capital sold 7 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022.
  • Sculptor Capital first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q1 2022 and held it in 3 quarters.
  • Sculptor Capital's Eucrates Biomedical Acquisition Corp. Unit position peaked at $780K in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on Sculptor Capital's 13F filing for Q4 2022, filed 14 Feb 2023.